Clinical trials
Phase 3 Ascites trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 4 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Unknown status | 5 |
| Recruiting | 2 |
| Terminated | 2 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Otsuka Pharmaceutical Co., Ltd. | 3 |
| Sanofi | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | 2 |
| Aleksander Krag | 1 |
| Asian Institute of Gastroenterology, India | 1 |
| Centre Hospitalier Universitaire de Besancon | 1 |
| Centro Medico Issemym | 1 |
| Erasmus Medical Center | 1 |
| Grifols Therapeutics LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ascites | 28 |
| Fibrosis | 9 |
| Liver Cirrhosis | 9 |
| Hepatorenal Syndrome | 2 |
| Acute Kidney Injury | 1 |
| Carcinoma, Hepatocellular | 1 |
| Hepatitis, Alcoholic | 1 |
| Hernia | 1 |
| Hernia, Umbilical | 1 |
| Hypertension, Portal | 1 |
Trials
Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.